Testing TRX103 to Help Prevent Graft-Versus-Host Disease After Stem Cell Transplant
Tests TRX103 cells, given once after transplant, in adults with blood cancers.
Key facts
- Who runs it
- Tr1X, Inc.
- Where
- Boston, Duarte, Minneapolis, New York, and Seattle, United StatesSee the 5 sites
- Trial code
- Registry title
- Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 36 people, planned
- Started
- 8 Apr 2024
- Expected to end
- 15 Apr 2027
- Type of study
- Interventional
- Treatments tested
- TRX103
- Record updated
- 15 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with certain blood cancers who are about to have a stem cell transplant from a partly matched donor. It tests the safety of TRX-103, given once after the transplant.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Acute lymphoblastic leukemia (B- or T-cell), acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia. Over 65 with intense conditioning: HSCT-comorbidity index score below 5.
- Earlier treatment
- No earlier donor stem cell transplant (bone marrow, blood or cord blood). No other investigational drug within 28 days (or 5 half-lives, whichever is shorter) of conditioning.
- Biomarker or test result
- A half-matched related (haploidentical) or unrelated donor must be available. Hepatitis B surface antigen must be negative, or HBV PCR negative.
Main reasons for not taking part
- Earlier donor stem cell transplant
- HIV positive
- Serious kidney, liver, lung or heart problems
- Uncontrolled infection or other serious illness
- Pregnant, breast feeding or planning pregnancy during the study
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Subjects with one of the following hematologic malignancies: Acute Lymphoblastic Leukemia (B- or T-ALL), Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), or Chronic myelomonocytic leukemia (CMML)
- Males and Females Age ≥ 18 years
- Weight of ≥ 35 Kg
- Karnofsky performance status ≥ 70 %
- Available mismatched related (haploidentical) or unrelated donors for peripheral blood stem cell (PBSC) donation
- Subjects must otherwise fulfill institutional criteria for eligibility to undergo allogeneic stem cell transplantation
- Absence of uncontrolled bacterial, viral or fungal infection at time of enrollment
- Have adequate organ function
- Subjects > 65-year-old receiving MAC conditioning will only be eligible if they have a HSCT-comorbidity index score < 5
- Subjects must be able to understand and sign informed consent and be willing and able to complete all specified procedures and visits
Who cannot take part
- Prior allogeneic bone marrow, peripheral blood, or cord blood HSCT
- Positive hepatitis-C antibody with positive Recombinant Immunoblot Assay (RIBA) or PCR unless the subject has received curative anti-viral treatment and confirmed negative viral load by PCR
- Received another investigational agent for treatment of disease understudy within 28 days (or 5 half-lives, whichever is shorter) of conditioning and/or have not recovered from treatment related toxicities
- Subjects with a previous history of Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS) who are not good candidates for treatment with sirolimus
- Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction
- HIV positive
- Positive hepatitis-B surface antigen. Subject may be included if they are HBV PCR negative
- Any serious illness, uncontrolled inter-current illness, psychiatric illness, active or uncontrolled infection, or other medical condition or history, including laboratory results
- Subjects that are pregnant, breast feeding or aim to become pregnant during the study period. (Subjects must agree to use a highly effective method of contraception)
Where in United States
- Dana-Farber Cancer InstituteBoston, United StatesContact: John Koreth, MDTaking people
- City of HopeDuarte, United StatesContact: Tr1X Clinical TrialsTaking people
- University of MinnesotaMinneapolis, United StatesContact: Mark Juckett, MDTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Miguel-Angel Perales, MDTaking people
- Fred Hutchinson Cancer CenterSeattle, United StatesContact: Filippo Milano, MDTaking people
About the trial
What the trial wants to find out
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.
The group in the trial
- TRX-103Treatment being tested
TRX-103 will be infused on time post hematopoietic stem cell transplant (HSCT).
Treatment: TRX103
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
- Plain-language title
- Testing TRX103 to Help Prevent Graft-Versus-Host Disease After Stem Cell TransplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Engineering allogeneic type 1 regulatory T cells: a scalable, off-the-shelf platform for restoring immune tolerance.Frontiers in immunology, 2026
- Record updated
- 15 April 2025